Repare Therapeutics Inc. Share-based Payment Arrangement, Expense
Repare Therapeutics Inc. reported Share-based Payment Arrangement, Expense of $1.39 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2025-11-14
- Repare Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $1.39M, a 73.48% decline year-over-year.
- Repare Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $2.06M, a 68.46% decline year-over-year.
- Repare Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $3.96M, a 38.87% decline year-over-year.
- Repare Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2024-12-31 was $4.92M, a 22.66% decline year-over-year.
- Repare Therapeutics Inc. share-based payment arrangement, expense for fiscal 2024 was $23.16M, a 7.59% decline from fiscal 2023.
- Repare Therapeutics Inc. share-based payment arrangement, expense for fiscal 2023 was $25.06M, a 27.28% increase from fiscal 2022.
- Repare Therapeutics Inc. share-based payment arrangement, expense for fiscal 2022 was $19.69M, a 53.49% increase from fiscal 2021.
- Repare Therapeutics Inc. share-based payment arrangement, expense for fiscal 2021 was $12.83M, a 405.68% increase from fiscal 2020.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $1.39M 10-Q · filed 2025-11-14 | $3.45M derived: sum of 2 quarters · filed 2025-11-14 | $7.41M 10-Q · filed 2025-11-14 | $12.32M derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | $2.06M 10-Q · filed 2025-08-08 | $6.01M 10-Q · filed 2025-08-08 | $10.93M derived: sum of 3 quarters · filed 2025-08-08 | $16.18M derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-03-31 | $3.96M 10-Q · filed 2025-05-13 | $8.88M derived: sum of 2 quarters · filed 2025-05-13 | $14.12M derived: sum of 3 quarters · filed 2025-11-14 | $20.64M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $10.17M derived: sum of 2 quarters · filed 2025-11-14 | $16.68M derived: sum of 3 quarters · filed 2025-11-14 | $23.16M 10-K · filed 2025-03-03 |
| 2024-09-30 | $5.25M 10-Q · filed 2025-11-14 | $11.77M derived: sum of 2 quarters · filed 2025-11-14 | $18.24M 10-Q · filed 2025-11-14 | $24.60M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $6.52M 10-Q · filed 2025-08-08 | $12.99M 10-Q · filed 2025-08-08 | $19.35M derived: sum of 3 quarters · filed 2025-08-08 | $25.73M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $6.47M 10-Q · filed 2025-05-13 | $12.83M derived: sum of 2 quarters · filed 2025-05-13 | $19.21M derived: sum of 3 quarters · filed 2025-05-13 | $25.48M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $12.74M derived: sum of 2 quarters · filed 2025-03-03 | $19.00M derived: sum of 3 quarters · filed 2025-03-03 | $25.06M 10-K · filed 2025-03-03 |
| 2023-09-30 | $6.38M 10-Q · filed 2024-11-07 | $12.64M derived: sum of 2 quarters · filed 2024-11-07 | $18.70M 10-Q · filed 2024-11-07 | $23.84M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $6.26M 10-Q · filed 2024-08-06 | $12.33M 10-Q · filed 2024-08-06 | $17.46M derived: sum of 3 quarters · filed 2024-08-06 | $22.52M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $6.06M 10-Q · filed 2024-05-07 | $11.20M derived: sum of 2 quarters · filed 2024-05-07 | $16.25M derived: sum of 3 quarters · filed 2024-05-07 | $21.00M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $10.19M derived: sum of 2 quarters · filed 2024-02-28 | $14.94M derived: sum of 3 quarters · filed 2024-02-28 | $19.69M 10-K · filed 2024-02-28 |
| 2022-09-30 | $5.05M 10-Q · filed 2023-11-09 | $9.80M derived: sum of 2 quarters · filed 2023-11-09 | $14.55M 10-Q · filed 2023-11-09 | $18.45M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $4.75M 10-Q · filed 2023-08-09 | $9.50M 10-Q · filed 2023-08-09 | $13.40M derived: sum of 3 quarters · filed 2023-08-09 | $17.09M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $4.75M 10-Q · filed 2023-05-09 | $8.65M derived: sum of 2 quarters · filed 2023-05-09 | $12.34M derived: sum of 3 quarters · filed 2023-05-09 | $15.53M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $7.59M derived: sum of 2 quarters · filed 2023-02-28 | $10.77M derived: sum of 3 quarters · filed 2023-02-28 | $12.83M 10-K · filed 2023-02-28 |
| 2021-09-30 | $3.69M 10-Q · filed 2022-11-09 | $6.88M derived: sum of 2 quarters · filed 2022-11-09 | $8.93M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $3.18M 10-Q · filed 2022-08-04 | $5.24M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $2.06M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $2.54M 10-K · filed 2022-03-01 | |||
| 2019-12-31 | $511.00K 10-K · filed 2022-03-01 |